Helsinn Establishes New R&D Hub in the U.S. to Support its Global Fully Integrated Targeted Therapy (FITT) Strategy New R&D hub will be based at U.S. subsidiary, Helsinn Therapeutics (U.S.), Inc. (HTU)
Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer Lugano, Switzerland, May 19, 2022 – Helsinn Group, a fully integrated, global biopharma.
Helsinn appoints Dr Melanie Rolli as Group Chief Operating Officer Lugano, Switzerland, May 19, 2022 - Helsinn Group, a fully integrated, global biopharma company with a diversified pipeline